Core One Labs -- top oder flop? (Seite 2)

[J_Hobel]

Was ist das überhaupt core one labs?

[ooy]

Antwort auf Beitrag Nr.: 74.391.968 von javmp51 am 28.08.23 16:19:26

Hoffentlich...

[javmp51]

Das wird noch weiter abwärts gehen!!

[PersecutorTe1]

Böse,Böse

[PersecutorTe1]

Antwort auf Beitrag Nr.: 74.373.539 von Eezay am 24.08.23 14:46:43

Zitat von Eezay: Klassische Polli bruchbude... hier werden nur deutsche Anleger gemolken

Bruchbude hin oder her.
Ich werde hier auch bei der nächsten News satt einpacken.

[Eezay]

Antwort auf Beitrag Nr.: 74.373.092 von javmp51 am 24.08.23 13:32:21

Klassische Polli bruchbude... hier werden nur deutsche Anleger gemolken

[javmp51]

Was will mir dieser Beitrag zeigen??? Nichts, weil das absolut nichts neues ist. Bereits seit mehr als 5 Jahren wird von den ganzen Bigschiffen der Branche in diesem Bereich geforscht. Es soll auch bereits Präparate geben, die sehr weit sind, dass man innerhalb der nächsten 3-5 Jahren mit klinischen Tests anfangen kann. Nur Anmerkung zu COOL: diese Forschungen kosten zwischen 1,5 bis 5 Milliarden Euro. Woher COOL das Geld für die restlichen 99,8 % an weiteren Aufwand, der noch erforderlich sein wird bis zur Marktreife, ist mir schleierhaft! Und wenn auch nur ein Körnchen an Realität in den ganzen Veröffentlichungen wäre, wäre der Laden schon längst übernommen worden.

[PersecutorTe1]

Vancouver, British Columbia, Canada – August 23, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) applauds a recent survey study published in the European Journal of Pain, which suggests that psychedelic substances could offer potential therapeutic value in addressing specific chronic pain conditions.

By conducting an extensive survey among 170 individuals dealing with chronic pain and who met the inclusion criteria, the research aimed to uncover insights into the effectiveness of conventional treatments, full psychedelic doses, and psychedelic microdoses on five prevalent chronic pain conditions: fibromyalgia, arthritis, migraine, tension-type headache, and sciatica. These conditions were carefully selected based on consistent diagnostic criteria.

The outcomes of the survey were promising as participants, with the exception of those experiencing sciatica, consistently reported experiencing superior pain relief through the use of psychedelics compared to conventional medications across all the studied conditions. Particularly noteworthy was the observation that full psychedelic doses outperformed traditional treatments in terms of effectiveness. Microdoses also displayed significant potential, delivering substantial relief for migraines and comparable relief for the other chronic pain conditions investigated.

The study's significance lies in its contribution to the growing body of evidence supporting the therapeutic role of psychedelic substances and its analgesic effects among individuals suffering from fibromyalgia, arthritis, migraine, tension-type headache and sciatica. The authors of the study believe the findings hold tremendous implications for the advancement of future research endeavors concerning the practical utilization of psychedelics for pain management.

Core One Labs acknowledges the importance of this research as a steppingstone for further advancements in the field of chronic pain management and remains steadfast in supporting and encouraging any further studies and breakthroughs exploring psychedelic interventions aimed at addressing pain.

Engagement of Stride Report

The Company also announces that further to its news release of July 19, 2023, the Company has engaged Stride Report Inc. (“Stride”), an arm’s length party to the Company, to provide marketing and investor awareness services. The Company has agreed to pay to Stride a monthly non-refundable fee of CDN$10,000, plus applicable taxes, per month, for a period of four (4) months. The services will include investor relations, creation of content, strategic planning, digital advertisement placement, and overseeing progress and results of digital campaigns. Consideration offered to Stride does not include any securities of the Company. Aside from this engagement, the Company does not have any relationship with Stride and Mr. Raafat Nasser, CEO of Stride. Stride’s business address is located 1120 – 625 Howe Street, Vancouver, BC V6C 1T2, email is [e-mail], telephone number is 604-710-7318 and website is https://stride.report/.

Core One Labs Inc.

Joel Shacker
Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:
[e-mail]

[chris008]

Auf Polli ist immer Verlass.
Zu 100 Prozent 🥂

[Eezay]

Antwort auf Beitrag Nr.: 74.366.480 von Sanktblasien am 23.08.23 13:28:24

Zitat von Sanktblasien: Bin rechtzeitig ausgestiegen, ist mir alles zu unsicher. Setze jetzt auf Cannabis, vielleicht läufst da besser.

Der weed boom war 5 jahre vorbei ala ich 2019 an die Börse ging. Und 3 von Pollis weed buden sind frisch delisted.... ...... also viel Spaß beim Geld in dej ofe. Werfen 🤙